methotrexate has been researched along with Carcinoma, Squamous Cell of Head and Neck in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (66.67) | 24.3611 |
| 2020's | 9 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chhabra, N; Choudhary, R; Gupta, AK; Singh, A | 1 |
| Damerla, RR; Kamal, MV; Kumar, NAN; Pai, A; Palod, A; Rao, M; Sharan, K; Shetty, PS; Usman, N | 1 |
| Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL | 1 |
| Clement, PM; Cohen, EEW; Cupissol, D; de Souza Viana, L; Fayette, J; Gauler, T; Geng, Y; Geoffrois, L; Guigay, J; Haddad, R; Keilholz, U; Kornek, G; Licitra, L; Machiels, JP; Melichar, B; Rauch, D; Ribaldo Nicolau, U; Rolland, F; Tahara, M; Vermorken, J; Zanetta-Devauges, S; Zografos, E | 1 |
| Ahn, MJ; Arora, RS; Bello, M; Chan, A; Cohen, EEW; Dechaphunkul, A; Geng, Y; Guo, Y; He, X; Kamble, K; Kandil, A; Kang, JH; Kim, SB; Kumar, V; Li, P; Li, W; Tang, PZ; Wang, CH; Zhang, Q; Zografos, E | 1 |
| Abraham, G; Banavali, S; Bhattacharjee, A; Chandrasekharan, A; Das, S; Dhumal, S; DSouza, H; Gota, V; Joshi, A; Kashyap, L; Kumar, S; Mahajan, A; Mahimkar, M; Menon, N; Mukadam, S; Nawale, K; Noronha, V; Pandey, M; Patil, VM; Prabhash, K; Sable, N; Simha, V; Solanki, B; Srinivas, S; Talreja, V | 1 |
| Ji, M; Wei, W; Wu, CP; Yang, X | 1 |
| Bins, S; Mathijssen, RHJ | 1 |
| Cohen, EEW; Harrington, KJ; Soulières, D; Swaby, RF | 1 |
| Beerepoot, LV; Fiets, WE; Ham, JC; Husson, O; Jeurissen, FJF; Jonker, MA; Slingerland, M; van der Graaf, WTA; van Herpen, CML; van Meerten, E | 1 |
| Ahn, MJ; Auclair, V; Berrocal, A; Bertolini, F; Castro, G; Cheung, WY; Chirovsky, D; Grünwald, V; Guillaume, X; Harrington, K; Joo, S; Kuyas, H; Shah, R; Sjoquist, K; Yang, MH | 1 |
| Lau, A; Li, KY; Su, YX; Yang, WF | 1 |
| -Maniglia, JV; Biselli-Chicote, PM; Goloni-Bertollo, EM; Maniglia, MP; Oliveira-Cucolo, JG; Pavarino, ÉC; Rodrigues-Fleming, GH; Russo, A | 1 |
| Chen, L; Ji, J; Liao, Q; Ma, X; Song, X; Zeng, H | 1 |
| Arasaki, A; Kawabata-Iwakawa, R; Kina, S; Kinjo, T; Miyamoto, S; Sunakawa, H | 1 |
| Abbasi, MM; Abdal, K; Abdollahi, B; Aghbali, AA; Fotohi, S; Hamishehkar, H; Khiavi, MM; Salehi, R; Sina, M | 1 |
| Burtness, B; Clement, PM; Cohen, EEW; Cong, XJ; Del Campo, JM; Dupuis, N; Ehrnrooth, E; Fayette, J; Gauler, T; Geoffrois, L; Gibson, N; Grau, JJ; Guigay, J; Haddad, RI; Krämer, N; Licitra, LF; Machiels, JH; Mailliez, A; Merlano, MC; Solca, F; Tahara, M; Vermorken, JB | 1 |
| Bergón-Sendín, M; Pulido-Pérez, A; Suárez-Fernández, R | 1 |
| Ahn, MJ; Burtness, B; Cheng, J; Cohen, EEW; Dinis, J; Harrington, KJ; Le Tourneau, C; Licitra, L; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Zhang, P | 1 |
| Assi, T; Bakouny, Z; El Karak, F; El Rassy, E; Ghosn, M; Pavlidis, N | 1 |
| Cocks, K; Contente, M; DeRosa, M; Shaw, JW; Simpson, S; Taylor, FC | 1 |
| Christiansen, H; Hermann, RM | 1 |
| Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
| Al-Rasheedy, I; Nichols, AC; Palma, DA; Stitt, L; Winquist, E | 1 |
| Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP | 1 |
| Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB | 2 |
| Bourhis, J; Economopoulou, P; Psyrri, A | 1 |
| Specenier, P; Vermorken, J | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Chen, D; Chen, H; Chen, M; Chen, S; Dong, Y; Hua, L; Li, M; Song, X; Zhang, C; Zhang, Y; Zheng, H; Zhu, M | 1 |
| Bardet, E; Benhamou, E; Bontemps, P; Bourhis, J; Calais, G; Daly-Schveitzer, N; Janot, F; Lapeyre, M; Lesaunier, F; Lusinchi, A; Maingon, P; Tao, Y; Tortochaux, J; Tournay, E; Verrelle, P | 1 |
| Brockstein, BE | 1 |
| DALY, JF; FRIEDMAN, M | 1 |
| ACQUARELLI, MJ; FEDER, RJ; GORDON, HE | 2 |
7 review(s) available for methotrexate and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Head and Neck Neoplasms; Humans; Methotrexate; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck | 2023 |
Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck | 2020 |
Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Network Meta-Analysis; Nivolumab; Progression-Free Survival; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Survival Analysis | 2019 |
Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Linear Models; Methotrexate; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Early Detection of Cancer; Head and Neck Neoplasms; Humans; Immunotherapy; Meta-Analysis as Topic; Methotrexate; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Papillomavirus Vaccines; Postoperative Care; Precision Medicine; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Therapies, Investigational | 2015 |
Afatinib in squamous cell carcinoma of the head and neck.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Management of recurrent head and neck cancer: recent progress and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Fluorouracil; Head and Neck Neoplasms; Humans; Methotrexate; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2011 |
13 trial(s) available for methotrexate and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Adherence and Compliance; Treatment Outcome | 2019 |
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Male; Methotrexate; Middle Aged; Mouth Neoplasms; Organoplatinum Compounds; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Quality of Life; Squamous Cell Carcinoma of Head and Neck | 2020 |
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Topics: Administration, Intravenous; Administration, Oral; Afatinib; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Disease-Free Survival; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2017 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck | 2019 |
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Follow-Up Studies; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Nivolumab; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Survival | 2019 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent.
Topics: Carcinoma, Squamous Cell; Cause of Death; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Palliative Care; Squamous Cell Carcinoma of Head and Neck | 2011 |
16 other study(ies) available for methotrexate and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
Oral Squamous Cell Carcinoma Following Acute Methotrexate Toxicity in a Psoriasis Patient: A Causal Association or Mere Co-Incidence.
Topics: Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Immunosuppressive Agents; Incidence; Methotrexate; Middle Aged; Mouth Neoplasms; Psoriasis; Squamous Cell Carcinoma of Head and Neck | 2023 |
p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brazil; Bridged-Ring Compounds; Canada; Cetuximab; Confidence Intervals; Europe; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Republic of Korea; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taiwan; Taxoids; Treatment Outcome | 2020 |
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Genetic Predisposition to Disease; Glutathione S-Transferase pi; Haplotypes; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Polymorphism, Genetic; Prognosis; Retrospective Studies; Risk Factors; Squamous Cell Carcinoma of Head and Neck | 2020 |
HPV infection related immune infiltration gene associated therapeutic strategy and clinical outcome in HNSCC.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD8-Positive T-Lymphocytes; Computational Biology; Datasets as Topic; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Lymphocytes, Tumor-Infiltrating; Methotrexate; Oligonucleotide Array Sequence Analysis; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Transcriptome; Tumor Microenvironment | 2020 |
A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Synergism; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Pyrazines; Pyridines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Tongue Neoplasms; Wnt Signaling Pathway; Young Adult | 2021 |
Comparison of injectable doxorubicin & its nanodrug complex chemotherapy for the treatment of 4-nitroquinoline-1-oxide induced oral squamous cell carcinoma in rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Carcinoma, Squamous Cell; Disease Models, Animal; Doxorubicin; Drug Delivery Systems; Head and Neck Neoplasms; Humans; Methotrexate; Nanoparticles; Rats; Squamous Cell Carcinoma of Head and Neck | 2017 |
Neoadjuvant intralesional methotrexate in squamous cell carcinoma of the lip.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Humans; Injections, Intralesional; Lip Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2019 |
[Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)].
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Self-targeted salinomycin-loaded DSPE-PEG-methotrexate nanomicelles for targeting both head and neck squamous cell carcinoma cancer cells and cancer stem cells.
Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Head and Neck Neoplasms; Humans; Male; Methotrexate; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplastic Stem Cells; Phosphatidylethanolamines; Polyethylene Glycols; Pyrans; Squamous Cell Carcinoma of Head and Neck | 2017 |
COMBINED IRRADIATION AND CHEMOTHERAPY IN THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
Topics: Carcinoma; Carcinoma, Squamous Cell; Head; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasms; Squamous Cell Carcinoma of Head and Neck | 1963 |
CONTINUOUS INTRA-ARTERIAL INFUSION OF METHOTREXATE FOR RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
Topics: Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA; DNA, Neoplasm; Drug Therapy; Folic Acid Antagonists; Head; Head and Neck Neoplasms; Infusions, Intra-Arterial; Infusions, Parenteral; Methotrexate; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Surgical Procedures, Operative; Temporal Arteries; Toxicology | 1964 |
COMPLICATIONS INHERENT IN CONTINUOUS INTRA-ARTERIAL CHEMOTHERAPY OF HEAD AND NECK CARCINOMA.
Topics: Carcinoma, Squamous Cell; Cerebrovascular Disorders; Embolism, Air; Head; Head and Neck Neoplasms; Humans; Infusions, Parenteral; Methotrexate; Myocardial Infarction; Neoplasms; Pneumonia; Pulmonary Atelectasis; Pulmonary Embolism; Sepsis; Squamous Cell Carcinoma of Head and Neck; Thrombophlebitis | 1964 |